Mabs | www.gmachineinfo.com | 全球机械文献资源网

OA期刊

ISSN	1942-0862
刊名	Mabs
出版商	Taylor & Francis Inc.
url	https://www.tandfonline.com/loi/kmab20
机构	Taylor & Francis Ltd.

全部

2010	2011	2012	2013	2014	2015
2016	2017	2018	2019	2020	2021
2022	2023	2024	2025

2017, vol.9, no.1	2017, vol.9, no.2	2017, vol.9, no.3	2017, vol.9, no.4	2017, vol.9, no.5	2017, vol.9, no.6
2017, vol.9, no.7	2017, vol.9, no.8

题名

作者

出版年

年卷期

Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults

Yunda Huang;Lily Zhang;Julie Ledgerwood;Nicole Grunenberg;Robert Bailer;Abby Isaacs;Kelly Seaton;Kenneth H. Mayer;Edmund Capparelli;Larry Corey;Peter B. Gilbert;

2017

2017, vol.9, no.5

Toward in vitro-to-in vivo translation of monoclonal antibody pharmacokinetics: Application of a neonatal Fc receptor-mediated transcytosis assay to understand the interplaying clearance mechanisms

Claudia A. Castro Jaramillo;Sara Belli;Anne-Christine Cascais;Sherri Dudal;Martin R. Edelmann;Markus Haak;Marie-Elise Brun;Michael B. Otteneder;Mohammed Ullah;Christoph Funk;Franz Schuler;Silke Simon;

2017

2017, vol.9, no.5

Contribution of physiologists to the identification of the humoral component of immunity in the 19th century

Yves-Marie Lahaie;Hervé Watier;

2017

2017, vol.9, no.5

Affinity of human IgG subclasses to mouse Fc gamma receptors

Gillian Dekkers;Arthur E. H. Bentlage;Tamara C. Stegmann;Heather L. Howie;Suzanne Lissenberg-Thunnissen;James Zimring;Theo Rispens;Gestur Vidarsson;

2017

2017, vol.9, no.5

Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates

Miroslav Dostalek;Thomayant Prueksaritanont;Robert F. Kelley;

2017

2017, vol.9, no.5

Challenges and opportunities for the future of monoclonal antibody development: Improving safety assessment and reducing animal use

Fiona Sewell;Kathryn Chapman;Jessica Couch;Maggie Dempster;Shawn Heidel;Lise Loberg;Curtis Maier;Timothy K. Maclachlan;Marque Todd;Jan Willem van der Laan;

2017

2017, vol.9, no.5

Antibodies targeting G protein-coupled receptors: Recent advances and therapeutic challenges

Mohammed Akli Ayoub;Pascale Crépieux;Markus Koglin;Marc Parmentier;Jean-Philippe Pin;Anne Poupon;Eric Reiter;Martine Smit;Jan Steyaert;Hervé Watier;Trevor Wilkinson;

2017

2017, vol.9, no.5

Single amino acid substitution in LC-CDR1 induces Russell body phenotype that attenuates cellular protein synthesis through eIF2α phosphorylation and thereby downregulates IgG secretion despite operational secretory pathway traffic

Haruki Hasegawa;Ann Hsu;Christine E. Tinberg;Karen E. Siegler;Aaron A. Nazarian;Mei-Mei Tsai;

2017

2017, vol.9, no.5

Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody

Atsuhiko Maeda;Yuki Iwayanagi;Kenta Haraya;Tatsuhiko Tachibana;Genki Nakamura;Takeru Nambu;Keiko Esaki;Kunihiro Hattori;Tomoyuki Igawa;

2017

2017, vol.9, no.5

Infliximab crystal structures reveal insights into self-association

Thomas F. Lerch;Penelope Sharpe;Stephen J. Mayclin;Thomas E. Edwards;Eunhee Lee;Hugh D. Conlon;Sharon Polleck;Jason C. Rouse;Yin Luo;Qin Zou;

2017

2017, vol.9, no.5